Myth-buster
All-cause mortality was statistically indistinguishable (RR 0.94, p=0.57) between vitamin K antagonists and DOACs in a meta-analysis of 3,863 heart valve patients — a null finding from a specific clinical context, not a verdict on vitamin K supplements.
This doesn't test whether vitamin K supplements affect mortality; it compares two types of anticoagulant drugs in a narrow patient group. The result means that in this population, blocking vitamin K's action (via warfarin) didn't shift death rates compared to newer alternatives — a reminder that sweeping claims about vitamin K and longevity need far more evidence.
The meta-analysis pooled data from 3,863 patients who had received a bioprosthetic heart valve and were randomized to either a vitamin K antagonist (like warfarin) or a direct oral anticoagulant (DOAC). The study found that the risk of death from any cause was virtually the same between the two groups (relative risk 0.94, with a wide confidence interval crossing 1.0, giving a p-value of 0.57). While the DOACs did reduce the risk of stroke or systemic embolism, the mortality result is null — and because this is among the first meta-analyses on this specific comparison, the finding should be interpreted with caution and not extrapolated to vitamin K supplementation in healthy people.
Where this fits in the evidence
This is among the first studies we've indexed on Vitamin K for Reduced All-Cause Mortality — treat it as an early signal until more research accumulates.
The study
- Meta-Analysis
- n = 3,863
- 2026-01
- Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.